论文部分内容阅读
目的:对参芪扶正注射液联合化疗治疗乳腺癌的疗效进行临床观察。方法:选取我院2012年12月~2014年7月间收治的72例乳腺癌患者,将其随机分治疗组36例,对照组36例。两组患者全部采用CAF化疗方案,治疗组在采取该方案的同时加用参芪扶正注射液,持续治疗两个疗程,对两组患者的临床疗效、不良反应、生活改善情况及免疫功能变化等进行全面对比分析。结果:治疗组患者的近期缓解率明显高于对于对照组;治疗组患者化疗不良反应发生率明显低于对照组;治疗组生活改善率明显高于对照组;治疗组治疗后CD3+、CD4+、CD4+/CD8+比值上升;但对照组治疗前后不存在显著差异。结论:参芪扶正注射液联合化疗治疗乳腺癌,不仅能够降低化疗不良反应发生率,而且能够通过调节细胞免疫功能提高疗效。
Objective: To observe the curative effect of Shenqi Fuzheng injection combined with chemotherapy on breast cancer. Methods: Seventy-two patients with breast cancer admitted to our hospital from December 2012 to July 2014 were randomly divided into treatment group (36 cases) and control group (36 cases). Two groups of patients with all the CAF chemotherapy, the treatment group in the program plus Shenqifuzheng injection, continuous treatment of two courses of treatment of the two groups of patients with clinical efficacy, adverse reactions, improved living conditions and changes in immune function A comprehensive comparative analysis. Results: The response rate of patients in the treatment group was significantly higher than that in the control group. The incidence of adverse reactions in the treatment group was significantly lower than that in the control group. The improvement rate in the treatment group was significantly higher than that in the control group. The CD3 +, CD4 +, CD4 + / CD8 + ratio increased; but there was no significant difference in the control group before and after treatment. Conclusion: Shenqi Fuzheng injection combined with chemotherapy for breast cancer can not only reduce the incidence of adverse reactions, but also improve the curative effect by regulating cellular immunity.